NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Ascending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00703-4764-81 | 00703-4764 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 3, 2016 | In Use | |
00703-4768-01 | 00703-4768 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 16, 2009 | Nov. 30, 2019 | In Use |
00703-4768-81 | 00703-4768 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 3, 2016 | In Use | |
55390-0114-05 | 55390-0114 | Paclitaxel | Paclitaxel | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 23, 2001 | July 31, 2013 | No Longer Used | |
70534-0001-00 | 70534-0001 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 27, 2022 | In Use | |
70860-0200-05 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Nov. 30, 2024 | In Use |
70860-0200-50 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0215-66 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 15, 2021 | Sept. 30, 2024 | In Use |
70860-0215-67 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 15, 2021 | Nov. 30, 2024 | In Use |
70860-0215-68 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov. 30, 2019 | April 30, 2024 | In Use |
25021-0255-05 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 1, 2024 | In Use | |
25021-0255-17 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 1, 2024 | In Use | |
25021-0255-50 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 1, 2024 | In Use | |
00480-3290-01 | 00480-3290 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 2, 2024 | In Use | |
24979-0710-51 | 24979-0710 | Paclitaxel | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | April 1, 2022 | In Use | |
60505-6230-04 | 60505-6230 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | April 1, 2022 | In Use | |
16714-0834-01 | 16714-0834 | Palonosetron | Palonosetron | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 29, 2018 | In Use | |
68001-0355-25 | 68001-0355 | Palonosetron | Palonosetron | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 30, 2018 | In Use | |
55111-0694-07 | 55111-0694 | Palonosetron | Palonosetron | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | March 23, 2018 | In Use | |
55111-0694-19 | 55111-0694 | Palonosetron | Palonosetron | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | March 23, 2018 | In Use | |
63323-0673-05 | 63323-0673 | Palonosetron | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 19, 2018 | In Use | |
63323-0673-89 | 63323-0673 | Palonosetron | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 19, 2018 | In Use | |
67184-0514-01 | 67184-0514 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 19, 2018 | In Use | |
67184-0515-02 | 67184-0515 | Palonosetron Hydrochloride | Palonosetron | 0.075 mg/1.5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 19, 2018 | In Use |
Found 10,000 results in 13 milliseconds — Export these results